Abstract Objective:To investigate the clinical application value of recombinant human erythropoietin on the patients with tumor related anemia.Method:110 patients with malignant tumor anemia were selected as the research object,according to random digit table,they were divided into combined ombined group( group A, n=60) and control group( group B, n=50).The incidence of adverse reactions,clinical curative effect,record count red blood cells(RBC),the level of hemoglobin(Hb) and hematocrit(HCT) variations of two groups before and after treatment were compared.Result:(1)20 cases of group A were markedly effective in 21 cases, clinical total effective rate was 68.3%,was obviously higher than that of groupB 48%, contrast differences were significant(P<0.05).(2)After the treatment,two groups of patients erythrocyte count, hemoglobin and hematocrit levels were higher than before treatment, growth in groupAwas higher than B group( P<0.05).(3)Two groups of patients had no serious adverse reactions occur, in A group, the incidence rate of 63.3% compared to group B 58.0%, difference was not statistically significant(P>0.05). Conclusion:The curative effect of chemotherapy combined with recombinant human erythropoietin on the patients with tumor related anemia element scheme is exactly, can effectively improve the symptoms of anemia, is worthy of clinical promotion.
|
|
|
|
|